Literature DB >> 21730297

Tryptase/Protease-activated receptor 2 interactions induce selective mitogen-activated protein kinase signaling and collagen synthesis by cardiac fibroblasts.

Jennifer L McLarty1, Giselle C Meléndez, Gregory L Brower, Joseph S Janicki, Scott P Levick.   

Abstract

The mast cell product, tryptase, has recently been implicated to mediate fibrosis in the hypertensive heart. Tryptase has been shown to mediate noncardiac fibroblast function via activation of protease-activated receptor 2 and subsequent activation of the mitogen-activated protein kinase pathway, including extracellular signal-regulated kinase 1/2. Therefore, we hypothesized that this pathway may be a mechanism leading to fibrosis in the hypertensive heart. Isolated adult cardiac fibroblasts were treated with tryptase, which induced activation of extracellular signal-regulated kinase 1/2 via protease-activated receptor 2. Blockade of protease activated receptor 2 with FSLLRY (10 μmol/L) and inhibition of the extracellular signal-regulated kinase pathway with PD98059 (10 μmol/L) prevented collagen synthesis in isolated cardiac fibroblasts stimulated with tryptase. In contrast, p38 mitogen-activated protein kinase and stress-activated protein/c-Jun N-terminal kinase were not activated by tryptase. Cardiac fibroblasts isolated from spontaneously hypertensive rats showed this same pattern of activation. Treatment of spontaneously hypertensive rats with FSLLRY prevented fibrosis in these animals, indicating the in vivo applicability of the cultured fibroblast findings. Also, tryptase induced a myofibroblastic phenotype indicated by elevations in α-smooth muscle actin and extra type III domain A (ED-A) fibronectin. Thus, the results from this study demonstrate the importance of tryptase for inducing a cardiac myofibroblastic phenotype, ultimately leading to the development of cardiac fibrosis. Specifically, tryptase causes cardiac fibroblasts to increase collagen synthesis via a mechanism involving activation of protease-activated receptor 2 and subsequent induction of extracellular signal-regulated kinase signaling.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21730297      PMCID: PMC3437478          DOI: 10.1161/HYPERTENSIONAHA.111.169417

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  27 in total

1.  Serum tryptase levels and markers of renal dysfunction in a population with chronic kidney disease.

Authors:  Ana Esther Sirvent; César González; Ricardo Enríquez; Javier Fernández; Isabel Millán; Xavier Barber; Francisco Amorós
Journal:  J Nephrol       Date:  2010 May-Jun       Impact factor: 3.902

2.  Mast cell tryptase stimulates human lung fibroblast proliferation via protease-activated receptor-2.

Authors:  I A Akers; M Parsons; M R Hill; M D Hollenberg; S Sanjar; G J Laurent; R J McAnulty
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2000-01       Impact factor: 5.464

3.  Expression of protease-activated receptor-2 during embryonic development.

Authors:  A L Jenkins; C Chinni; M R De Niese; B Blackhart; E J Mackie
Journal:  Dev Dyn       Date:  2000-07       Impact factor: 3.780

4.  Modified assay for determination of hydroxyproline in a tissue hydrolyzate.

Authors:  C A Edwards; W D O'Brien
Journal:  Clin Chim Acta       Date:  1980-06-10       Impact factor: 3.786

5.  Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease.

Authors:  R Querejeta; N Varo; B López; M Larman; E Artiñano; J C Etayo; J L Martínez Ubago; M Gutierrez-Stampa; J I Emparanza; M J Gil; I Monreal; J P Mindán; J Díez
Journal:  Circulation       Date:  2000-04-11       Impact factor: 29.690

6.  Differential integrin expression by cardiac fibroblasts from hypertensive and exercise-trained rat hearts.

Authors:  Maria Lonnett Burgess; Louis Terracio; Toshiro Hirozane; Thomas K Borg
Journal:  Cardiovasc Pathol       Date:  2002 Mar-Apr       Impact factor: 2.185

7.  Protease-activated receptor-1-mediated DNA synthesis in cardiac fibroblast is via epidermal growth factor receptor transactivation: distinct PAR-1 signaling pathways in cardiac fibroblasts and cardiomyocytes.

Authors:  Abdelkarim Sabri; Jacob Short; Jianfen Guo; Susan F Steinberg
Journal:  Circ Res       Date:  2002-09-20       Impact factor: 17.367

8.  Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis.

Authors:  Ramón Querejeta; Begoña López; Arantxa González; Eloy Sánchez; Mariano Larman; José L Martínez Ubago; Javier Díez
Journal:  Circulation       Date:  2004-08-16       Impact factor: 29.690

9.  Proliferative action of mast-cell tryptase is mediated by PAR2, COX2, prostaglandins, and PPARgamma : Possible relevance to human fibrotic disorders.

Authors:  Mónica B Frungieri; Stephan Weidinger; Viktor Meineke; Frank M Köhn; Artur Mayerhofer
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-23       Impact factor: 11.205

10.  Mast cells and tubulointerstitial fibrosis in patients with ANCA-associated glomerulonephritis.

Authors:  Shigeru Otsubo; Kosaku Nitta; Keiko Uchida; Wako Yumura; Hiroshi Nihei
Journal:  Clin Exp Nephrol       Date:  2003-03       Impact factor: 2.801

View more
  35 in total

Review 1.  The role of neuropeptides in adverse myocardial remodeling and heart failure.

Authors:  Alexander Widiapradja; Prasad Chunduri; Scott P Levick
Journal:  Cell Mol Life Sci       Date:  2017-01-17       Impact factor: 9.261

Review 2.  Novel Targets for Hypertension Drug Discovery.

Authors:  Lokesh Kumar Bhatt; Ishant Selokar; Dezaree Raut; Tahir Hussain
Journal:  Curr Hypertens Rep       Date:  2021-03-30       Impact factor: 5.369

3.  THE AUTOCRINE ROLE OF TRYPTASE IN PRESSURE OVERLOAD-INDUCED MAST CELL ACTIVATION, CHYMASE RELEASE AND CARDIAC FIBROSIS.

Authors:  Jianping Li; Shaiban Jubair; Scott P Levick; Joseph S Janicki
Journal:  IJC Metab Endocr       Date:  2015-11-24

Review 4.  Gender differences in non-ischemic myocardial remodeling: are they due to estrogen modulation of cardiac mast cells and/or membrane type 1 matrix metalloproteinase.

Authors:  Joseph S Janicki; Francis G Spinale; Scott P Levick
Journal:  Pflugers Arch       Date:  2013-02-16       Impact factor: 3.657

5.  The emerging prominence of the cardiac mast cell as a potent mediator of adverse myocardial remodeling.

Authors:  Joseph S Janicki; Gregory L Brower; Scott P Levick
Journal:  Methods Mol Biol       Date:  2015

6.  Non-human primate and rat cardiac fibroblasts show similar extracellular matrix-related and cellular adhesion gene responses to substance P.

Authors:  Giselle C Meléndez; Edward J Manteufel; Heather M Dehlin; Thomas C Register; Scott P Levick
Journal:  Heart Lung Circ       Date:  2014-12-05       Impact factor: 2.975

7.  A brief exposure to tryptase or thrombin potentiates fibrocyte differentiation in the presence of serum or serum amyloid p.

Authors:  Michael J V White; Elkin Galvis-Carvajal; Richard H Gomer
Journal:  J Immunol       Date:  2014-11-26       Impact factor: 5.422

Review 8.  Could interferon-gamma be a therapeutic target for treating heart failure?

Authors:  Scott P Levick; Paul H Goldspink
Journal:  Heart Fail Rev       Date:  2014-03       Impact factor: 4.214

Review 9.  The Biological Basis for Cardiac Repair After Myocardial Infarction: From Inflammation to Fibrosis.

Authors:  Sumanth D Prabhu; Nikolaos G Frangogiannis
Journal:  Circ Res       Date:  2016-06-24       Impact factor: 17.367

10.  Dynamic mast cell-stromal cell interactions promote growth of pancreatic cancer.

Authors:  Ying Ma; Rosa F Hwang; Craig D Logsdon; Stephen E Ullrich
Journal:  Cancer Res       Date:  2013-04-30       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.